Sweden’s Orexo Forms Partnership With Shanghai’s NovaMed To Enter Chinese Oncology Market
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Swedish pharmaceutical firm Orexo has signed an agreement with Shanghai-based NovaMed for the distribution of Orexo's cancer pain treatment Abstral (fast-dissolving fentanyl) in China
You may also be interested in...
Novamed In-Licenses Products from Iroko and EUSA To Strengthen Cardiovascular And Oncology Pipeline
SHANGHAI - NovaMed Pharmaceuticals announced July 10 it has reached agreements with U.S.-based Iroko and U.K. firm EUSA Pharma to in-license Iroko's cardiovascular drugAggrastat (tirofiban) and EUSA's oncology drug Erwinase (crisantaspase)
Novamed In-Licenses Products from Iroko and EUSA To Strengthen Cardiovascular And Oncology Pipeline
SHANGHAI - NovaMed Pharmaceuticals announced July 10 it has reached agreements with U.S.-based Iroko and U.K. firm EUSA Pharma to in-license Iroko's cardiovascular drugAggrastat (tirofiban) and EUSA's oncology drug Erwinase (crisantaspase)
NovaMed CEO Mark Lotter On Working With Pharma Distributors In China: An Interview With PharmAsia News
Shanghai-based NovaMed Pharmaceuticals was founded in August 2005 to provide distribution services for multinational pharmaceutical companies in China. NovaMed has signed China deals with several multinationals, including Baxter, Pfizer and Sanofi-Aventis. NovaMed Founder and CEO Mark Lotter recently participated in an email interview with PharmAsia News' Shanghai bureau about the changing contours of the pharmaceutical sector in China.